# US 2023/0272020 A1 · Modified semaphorin 3a, compositions comprising the same and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272020 A1
- Document ID: US20230272020A1
- Status: Published application
- Kind: A1
- Application number: 17/928,685
- Filed: 2021-06-03
- Published: 2023-08-31
- Earliest claimed: 2020-06-04
- Assignees: Medical Research & Development Fund for Health Services Bnai Zion Medical Center; Technion Research & Development Foundation Limited; The Chancellor, Masters and Scholars of the University of Oxford
- Applicants: Medical Research & Development Fund for Health Services Bnai Zion Medical Center; Technion Research & Development Foundation Limited; The Chancellor, Masters and Scholars of the University of Oxford
- Inventors: Zahava VADASZ; Elias TOUBI; Nasren EIZA; Adi SABAG; Gera NEUFELD; Ofra KESSLER; E. Yvonne JONES
- Web page: https://patentgrep.com/patent/US20230272020A1

## CPC

- C07K 14/47: from mammals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 14/4703: {Inhibitors; Suppressors}
- C07K 14/70503: {Immunoglobulin superfamily}
- C12N 15/86: Viral vectors
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are modified forms of Semaphorin 3A (Sema3A) polypeptide having one or more amino acid substitutions and/or deletions compared to a wild type Sema3A protein. Further provided are nucleic acid molecules encoding the modified Sema3A polypeptide, compositions including the same and uses thereof in treating various immune-related conditions.

## Claims

### Claim at position 1

-29. (canceled)

### Claim 30

A modified Semaphorin 3A polypeptide, said modified Semaphorin 3A polypeptide comprising an amino acid replacement at a position corresponding to position 257 in a wild type Semaphorin 3A protein having an amino acid sequence as denoted by SEQ ID NO: 1, wherein the replacement is with Cysteine (C); and a deletion of at least 100 amino acids of the C-terminal region of the corresponding wild type Semaphorin 3A.

### Claim 31 (depends on 30)

The modified Semaphorin 3A polypeptide according to claim 30, wherein the amino acid substitution is S257C and the C-terminal deletion is of amino acids 517-771 of the corresponding wild type Semaphorin 3A.

### Claim 32 (depends on 31)

The modified Semaphorin 3A polypeptide according claim 31, wherein the modified Semaphorin 3A and the wild type Semaphorin 3A are of human origin.

### Claim 33 (depends on 30)

The modified Semaphorin 3A polypeptide according to claim 30, wherein the polypeptide further comprises a Tag sequence at the N-terminus and/or the C-terminus thereof.

### Claim 34 (depends on 30)

The modified Semaphorin 3A polypeptide according to claim 30, comprising an amino acid sequence as denoted by SEQ ID NO: 3.

### Claim 35 (depends on 30)

The modified Semaphorin 3A polypeptide according to claim 30, comprising an amino acid sequence as denoted by SEQ ID NO: 5.

### Claim 36 (depends on 30)

The modified Semaphorin 3A polypeptide according to claim 30, capable of forming a homo-dimer with a modified Semaphorin 3A polypeptide via S-S bonds formed between Cysteine 257 in each of the modified polypeptides.

### Claim 37 (depends on 30)

The modified Semaphorin 3A polypeptide according to claim 30, wherein the polypeptide is capable of binding CD72 receptor.

### Claim 38 (depends on 30)

The modified Semaphorin 3A polypeptide according to claim 30, wherein the polypeptide is un-capable of binding to Nrp1 and/or wherein the polypeptide is unable to induce cell contraction.

### Claim 39 (depends on 30)

The modified Semaphorin 3A polypeptide according to claim 30, wherein the polypeptide is capable of affecting expression of one or more anti-inflammatory cytokines.

### Claim 40 (depends on 30)

The modified Semaphorin 3A polypeptide according to claim 30, capable of inducing expression of IL-10 in CD4+ regulatory T-cells.

### Claim 41 (depends on 30)

A composition comprising the modified Semaphorin 3A polypeptide according to claim 30.

### Claim 42 (depends on 30)

A nucleic acid molecule encoding the modified Semaphorin 3A of claim 30.

### Claim 43 (depends on 42)

The nucleic acid molecule according to claim 42, comprising a nucleotide sequence as denoted by any one of SEQ ID NO: 4 and SEQ ID NO: 6.

### Claim 44 (depends on 42)

A vector comprising the nucleic acid molecule of claim 42.

### Claim 45 (depends on 30)

A method of treating an immune related condition in a subject in need thereof, the method comprising administering to the subject in need thereof a therapeutically effective amount of the modified Sema3A polypeptide according to claim 30, or a composition comprising the same.

### Claim 46 (depends on 42)

A method of treating an immune related disorder in a subject in need thereof, the method comprising administering to the subject in need thereof a therapeutically amount of the nucleic acid molecule according to claim 42, or a vector comprising the same.

### Claim 47 (depends on 42)

A host cell comprising the nucleic acid molecule according to claim 42.

### Claim 48 (depends on 44)

A host cells transformed or transfected with the vector according to claim 44.

### Claim 49 (depends on 30)

A host cell comprising the modified Semaphorin 3A polypeptide according to claim 30.
